Tonix Pharmaceuticals Hol...

AI Score

XX

Unlock

17.86
0.67 (3.90%)
At close: Apr 25, 2025, 3:59 PM
17.70
-0.92%
After-hours: Apr 25, 2025, 05:56 PM EDT

Tonix Pharmaceuticals Statistics

Share Statistics

Tonix Pharmaceuticals has 6.88M shares outstanding. The number of shares has increased by 2964.8% in one year.

Shares Outstanding 6.88M
Shares Change (YoY) 2964.8%
Shares Change (QoQ) 14.77%
Owned by Institutions (%) 0%
Shares Floating 6.88M
Failed to Deliver (FTD) Shares 445
FTD / Avg. Volume 0.03%

Short Selling Information

The latest short interest is 919.91K, so 14.3% of the outstanding shares have been sold short.

Short Interest 919.91K
Short % of Shares Out 14.3%
Short % of Float 14.3%
Short Ratio (days to cover) 1

Valuation Ratios

The PE ratio is -0.19 and the forward PE ratio is -3.63. Tonix Pharmaceuticals's PEG ratio is 0.01.

PE Ratio -0.19
Forward PE -3.63
PS Ratio 2.41
Forward PS 0.2
PB Ratio 0.17
P/FCF Ratio -0.4
PEG Ratio 0.01
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Tonix Pharmaceuticals.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 6.5, with a Debt / Equity ratio of 0.06.

Current Ratio 6.5
Quick Ratio 6.04
Debt / Equity 0.06
Debt / EBITDA -0.11
Debt / FCF -0.13
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $124.62K
Profits Per Employee $-1.61M
Employee Count 81
Asset Turnover 0.06
Inventory Turnover 0.92

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -96.65% in the last 52 weeks. The beta is 1.51, so Tonix Pharmaceuticals's price volatility has been higher than the market average.

Beta 1.51
52-Week Price Change -96.65%
50-Day Moving Average 15.47
200-Day Moving Average 25.1
Relative Strength Index (RSI) 49.56
Average Volume (20 Days) 1.66M

Income Statement

In the last 12 months, Tonix Pharmaceuticals had revenue of 10.09M and earned -130.04M in profits. Earnings per share was -176.6.

Revenue 10.09M
Gross Profit 2.33M
Operating Income -136.7M
Net Income -130.04M
EBITDA -71.73M
EBIT -75.15M
Earnings Per Share (EPS) -176.6
Full Income Statement

Balance Sheet

The company has 98.78M in cash and 8.12M in debt, giving a net cash position of 90.66M.

Cash & Cash Equivalents 98.78M
Total Debt 8.12M
Net Cash 90.66M
Retained Earnings -730.69M
Total Assets 162.89M
Working Capital 100.69M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -60.92M and capital expenditures -120K, giving a free cash flow of -61.05M.

Operating Cash Flow -60.92M
Capital Expenditures -120K
Free Cash Flow -61.05M
FCF Per Share -82.9
Full Cash Flow Statement

Margins

Gross margin is 23.07%, with operating and profit margins of -1354.28% and -1288.25%.

Gross Margin 23.07%
Operating Margin -1354.28%
Pretax Margin -1288.25%
Profit Margin -1288.25%
EBITDA Margin -710.61%
EBIT Margin -1354.28%
FCF Margin -604.77%

Dividends & Yields

TNXP does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for TNXP is $585, which is 3309.1% higher than the current price. The consensus rating is "Strong Buy".

Price Target $585
Price Target Difference 3309.1%
Analyst Consensus Strong Buy
Analyst Count 2
Stock Forecasts

Stock Splits

The last stock split was on Feb 5, 2025. It was a backward split with a ratio of 1:100.

Last Split Date Feb 5, 2025
Split Type backward
Split Ratio 1:100

Scores

Altman Z-Score -4.41
Piotroski F-Score 5